OXFORD, England and SAN DIEGO, April 22, 2010 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that it will be a product provider at the InnovHealth - Middle East Healthcare Innovations Summit in Abu Dhabi on 25 and 26 April 2010 and will be presenting the Enigma (Mini Laboratory) instrument system.
The Enigma ML is a fully automated, multi-sample, multi-plexing diagnostic instrument with integrated sample preparation and will deliver results from swab samples in less than 60 minutes, allowing clinical professionals to 'test and treat' in a single appointment. This simple to use system which requires minimal operator training, combines the speed and sensitivity of real-time PCR (polymerase chain reaction) to provide laboratory standard results.
InnovHealth 2010, organised by business information company naseba and endorsed by the UAE Ministry of Health, recognises Enigma as a pioneer in providing innovative healthcare solutions to the regions' progressing healthcare industry. Facilitating strategic networking, the event hosts the region's high-profile healthcare leaders, all of whom will benefit from informative conference sessions and panel discussions during the two-day summit.
About Enigma Diagnostics Limited
Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralized and point-of-care settings.
Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialisation strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of-care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.
Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licences from Applied Biosystems and Celera Diagnostics for commercialisation of real-time PCR instruments, and from Roche Molecular Systems to practise HybProbe real-time PCR chemistry for human and veterinary in vitro diagnostics. Enigma's in-house RandD activities have generated a portfolio of worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.
For more information visit http://www.enigmadiagnostics.com
UK Contact: Enigma Diagnostics Deborah Cordingley deborah.cordingley@enigmadiagnostics.com +44-1980-590131
SOURCE: Enigma Diagnostics Limited
CONTACT: Enigma Diagnostics: Deborah Cordingley,deborah.cordingley@enigmadiagnostics.com, +44-1980-590131
Comments